Products

xT CDx
Tempus
Lab & Diagnostics
Tempus xT CDx is an FDA-approved, 648-gene Next Generation Sequencing (NGS) test for comprehensive molecular profiling of solid malignant tumors, including companion diagnostic claims for colorectal cancer.
Tempus ECG-Low EF
Tempus
Cardiology AI
Tempus ECG-Low EF is an FDA-cleared AI software that analyzes 12-lead ECG recordings to detect signs associated with low left ventricular ejection fraction (LVEF ≤40%) in patients 40 years or older at risk of heart failure. It provides a binary output to aid clinicians in further evaluation.

See all 2 products →

About Tempus

Tempus is a healthcare technology company that leverages artificial intelligence to advance precision medicine. The company has built one of the world’s largest libraries of multimodal clinical and molecular data, which includes genomic sequences, pathology slides, radiology images, and electronic health records, all linked to patient outcomes. This extensive dataset, combined with AI-enabled analytics, allows Tempus to provide physicians with intelligent diagnostics and actionable insights at the point of care, aiming to personalize patient treatment and improve outcomes.

Tempus’s approach extends beyond oncology, its initial focus, to other disease areas such as neuropsychiatry, cardiology, and infectious diseases. For physicians, this means access to advanced genomic sequencing and other diagnostic tests that integrate unique patient information to offer more insightful results. The company’s platforms and tools, such as Tempus Next, are designed to identify care gaps and support adherence to the latest guideline-directed treatments, ultimately striving to make precision medicine a practical reality in everyday clinical practice.

Focus Areas

precision medicine artificial intelligence genomic testing oncology cardiology radiology pharmacogenomics clinical trial acceleration drug discovery real-world data digital pathology

Business Intelligence

Technologycloud-native, AI operating system, multimodal data platform (genomic, clinical, imaging, pathology), generative AI, LLM-powered tools

What Physicians Need to Know

Precision Medicine & AI
Tempus aims to make precision medicine practical at scale by embedding AI into diagnosis, treatment selection, and drug development workflows. They leverage one of the world's largest libraries of clinical and molecular data to provide AI-enabled solutions. This integrated approach allows for data-driven decisions and personalized patient care.
Genomic Testing
Tempus offers comprehensive genomic profiling (CGP) that analyzes hundreds of cancer-related genes from tumor tissue or blood samples. They perform both DNA and RNA sequencing to identify actionable mutations and fusions, providing insights for targeted treatment options. Their tests help identify clinically relevant genomic alterations, explore immunotherapy options, and assess eligibility for clinical trials. Tempus also offers liquid biopsy panels (xF and xF+) to detect oncogenic drivers and resistance mutations, and can be used for longitudinal testing. A key differentiator is their tumor-normal matched sequencing, which eliminates false positives in somatic variant calling and can identify germline variants.
Oncology
Oncology is Tempus' historical core and primary focus. They provide precision oncology solutions that offer a comprehensive view of patients and allow for customized treatment. Their AI-driven insights combine molecular and clinical data to help oncologists make informed decisions throughout the patient journey. Tempus offers a robust portfolio of oncology tests, including germline and somatic testing, MRD, and treatment response monitoring. Their Tempus Next Pathways applies AI to improve adherence to clinical guidelines, identify and contextualize cancer patients, and surface precision care pathways at the point of care.
Cardiology
Tempus has expanded its solutions into cardiology, where multimodal data and AI can make a difference. They offer AI-enabled solutions that increase productivity and save time diagnosing a wide range of heart conditions with fast, automated, and repeatable analysis powered by cardiac MR images.
Radiology
Tempus provides AI-enabled radiology solutions that turn medical images into actionable insights for more informed diagnostic and treatment decisions. Their 'Pixel' solution optimizes how radiologists read images, detect findings, generate reports, and share insights. It offers automated quantification, tracking, and reporting for therapy response evaluation and lung nodule detection.
Pharmacogenomics (PGx)
Tempus offers pharmacogenomic testing (Tempus nP) to inform medication selection and dosing for patients with mental health conditions like depression, anxiety, and ADHD. PGx testing identifies genetic variants that influence how patients metabolize certain therapies, helping assess potential toxicity risks and optimize treatment. They also provide rapid PGx testing (powered by OneOme) with results in 3-5 days, which can be integrated with tissue and liquid biopsy sequencing.
Clinical Trial Acceleration
Tempus accelerates clinical trials by identifying eligible patients and streamlining the enrollment process. Their TIME Trial® Program provides providers with access to a portfolio of clinical trials, expanding treatment options for patients. They use AI-enabled platforms like Tempus Next Trials to help research sites accelerate enrollment.
Drug Discovery
Tempus supports drug discovery by providing real-world multimodal clinical, molecular, and imaging data to accelerate therapy development. They leverage their vast dataset and AI to identify novel targets, optimize clinical trials, and generate evidence. Their platform, Tempus Lens, is designed for oncology drug development, enabling cohort assembly, trial simulation, and evidence generation.
Real-World Data (RWD)
Tempus has built one of the world's largest libraries of multimodal data, including clinical records, molecular data, imaging, and outcomes. This data is used to support better algorithms, applications, and research tools. They provide de-identified, structured RWD to pharmaceutical companies for research and development. Tempus also uses RWD to measure the impact of interventions, such as with their Tempus PRO™ for mental health.
Digital Pathology
Tempus offers AI-enabled digital pathology solutions to increase diagnostic confidence, improve workflow efficiency, and uncover deeper insights from samples. They have partnered with Paige to develop applications like Paige Prostate Detect, which aids in the primary diagnosis of prostate cancer and decreases pathologists' reading times. Tempus also uses AI to predict tissue sample viability for genomic testing, optimizing tissue use and surfacing earlier insights.
Physician Tip

Tempus offers several tools and services designed to empower physicians. Tempus ONE is a voice-enabled, portable device that provides real-time access to clinical insights and data from Tempus' genomic reports. It can answer questions about patient conditions, genomic information, and test status. Tempus ONE also integrates with EHR systems, offering features like pre-appointment preparation, real-time support during appointments (transcribing conversations, taking notes), and post-appointment assistance (documentation, treatment planning, prior authorizations, clinical trial matching). The Tempus Hub acts as a central nervous system for clinics, allowing providers to order tests, review results, and query patient history. Tempus' solutions are designed to integrate seamlessly into existing EHR and practice workflows, reducing cognitive load and preventing burnout. They provide high-quality, actionable information in a clear and physician-friendly format. For mental health, Tempus nP PGx reports incorporate FDA and CPIC guidelines, saving clinicians time and providing accurate, up-to-date clinical evidence.

Tempus emphasizes seamless integration with existing clinical workflows and systems. They integrate with major EHR systems like Epic and Cerner, eliminating data silos. Their platforms, such as Tempus ONE and Tempus Hub, are designed to work within the EHR, making it easy to access insights, order tests, and take action. Tempus also integrates with lab instruments like Illumina and Thermo Fisher. They have established data pipelines to facilitate the exchange of data between healthcare providers, diagnostic companies, and life science companies.

Products by Tempus

2 products in the directory

xT CDx
Tempus
Lab & Diagnostics
Tempus xT CDx is an FDA-approved, 648-gene Next Generation Sequencing (NGS) test for comprehensive molecular profiling of solid malignant tumors, including companion diagnostic claims for colorectal cancer.
Tempus ECG-Low EF
Tempus
Cardiology AI
Tempus ECG-Low EF is an FDA-cleared AI software that analyzes 12-lead ECG recordings to detect signs associated with low left ventricular ejection fraction (LVEF ≤40%) in patients 40 years or older at risk of heart failure. It provides a binary output to aid clinicians in further evaluation.

What the Web Says

Tempus is a technology company focused on precision medicine, utilizing AI and a large dataset of clinical and molecular information to assist with diagnostics and treatment in areas like oncology. They offer genomic testing panels, AI diagnostic tools, and a generative AI clinical assistant. While some employees praise the company's mission-driven culture, collaborative environment, and opportunities for growth in a rapidly evolving field, others express significant concerns about management, work-life balance, and compensation.

Overall: Mixed

Strengths

  • Meaningful work and mission-driven culture focused on healthcare innovation.
  • Collaborative environment with smart and talented coworkers.
  • Opportunities to learn and grow in AI, genomics, and healthcare technology.
  • Comprehensive healthcare coverage for employees.
  • Advanced AI-powered precision medicine platform with FDA-cleared diagnostic tools.
  • Free snacks and beverages in some office locations.

Limitations

  • Poor work-life balance and long hours.
  • Disorganized and toxic workplace culture with issues in management.
  • Low pay and negligible upward mobility, with promotions based on tenure rather than merit.
  • Lack of 401K matching and poor benefits for some positions.
  • Difficulty with product usability and customer support for some Tempus products.
  • Issues with billing and refunds for some customers.

Based on reviews from: Indeed.com, Tempus.com, YouTube.com, Clinical AI Report, AI-Health-Apps.com, SoftwareAdvice.com, Trustpilot.com, Nebula.org, Reddit.com, Capterra.com, G2.com, BuiltIn.com

Last updated: 2026-10-29

Videos

News, demos, and interviews about Tempus.

Loading videos...

Videos load interactively. If none appear, search YouTube for Tempus →

View all on YouTube

Press & Coverage

Morningstar
Tempus AI Expands Bristol Myers Partnership With Multi-Year Oncology, AI Data Deals
Tempus AI has signed a multi-year agreement with Bristol Myers Squibb (BMS) to license oncological data and provide access to its AI-powered platform, Lens Platform, for oncology drug development. This collaboration, running through 2031, aims to support biological and clinical insight, novel drug target discovery, and therapeutic development across BMS's oncology portfolio. Additionally, clinical-stage technology firm Pathos AI is broadening its strategic collaborations with both BMS and Tempus AI to build specialized datasets and AI capabilities for Alzheimer's disease and other neurological conditions.
2026-10
tempus.com
Tempus Announces Multi-Year Collaboration with Moderna and Merck
Tempus announced an expanded, multi-year collaboration with Moderna and Merck to support the potential commercialization of intismeran autogene (V940/mRNA-4157), an individualized neoantigen therapy being evaluated in combination with KEYTRUDA® for various cancer types. Tempus will manage the collection and transfer of tumor tissue and blood samples for next-generation sequencing (NGS) and will also provide NGS services to support the therapy's design and manufacturing process.
2026-10
tempus.com
Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation
Tempus received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-MR, an AI product that analyzes standard 12-lead resting electrocardiograms (ECGs) to detect signs associated with undiagnosed moderate or severe mitral regurgitation (MR). This marks another FDA-cleared device in Tempus' cardiovascular portfolio, aiming to identify patients at risk for complex cardiac conditions.
2026-09
gsmedtech.com
Tempus AI acquires Center Health, expanding into AI-powered diabetes management
Tempus AI has acquired Center Health, an AI-powered chronic disease management company known for its virtual health coaching platform for diabetes, prediabetes, and weight management. This acquisition expands Tempus' multimodal data and AI platform beyond its existing focus on oncology diagnostics and genomic testing into chronic metabolic disease management.
2026-09
tempus.com
Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs
Tempus AI, Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-PH, an AI-enabled software device that analyzes standard 12-lead electrocardiograms (ECGs) for signs associated with pulmonary hypertension. This is the third FDA-cleared device in Tempus' cardiovascular portfolio, aimed at identifying patients at risk for complex cardiac conditions.
2026-08
beckershospitalreview.com
Tempus AI to acquire cancer genomics firm for $1.5B
Tempus AI has agreed to acquire the cancer genomics company Personalis in a deal valued at approximately $1.5 billion. This acquisition builds on a previous partnership and aims to combine Personalis' minimal residual disease (MRD) technology with Tempus' existing AI-driven precision oncology platform to improve cancer patient monitoring.
2026-07
tempus.com
Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care
Tempus announced the publication of its study, “Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non-small cell lung cancer,” in JAMA Network Open. The study found that concurrent RNA- and DNA-based next-generation sequencing (NGS) led to the detection of more actionable structural variants compared to DNA sequencing alone in over 5,500 patients with advanced non-small cell lung cancer.
2024-11
tempus.com
Tempus Announces $275 Million in Funding
Tempus announced additional funding of approximately $275 million through a combination of equity from existing investors and debt financing from funds managed by Ares Management, bringing its total raised to over $1.3 billion. The funds will be used to scale operations and capabilities, focusing on building its disease-agnostic platform to aggregate de-identified data and develop insights for intelligent diagnostics.
2022-10
No FAQs available yet for this company.

Investors

Who's funded Tempus.

Related Companies

SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]

NTL Healthcare is a South Korean AI-powered women’s health company specializing in cervical cancer screening and diagnostics. The company has a history dating back to 1996 when it first introduced an analog cervical cancer reading system, Cervicography, to Korea. Since then, NTL Healthcare has evolved its technology, developing the world’s first remote uterine cervical cancer […]

Lumonus is a healthcare technology company that specializes in AI-powered solutions for cancer care, particularly in radiation oncology. The company’s core offering is the Lumonus AI platform, a digital oncology system with AI-native clinical infrastructure designed to automate and orchestrate critical oncology workflows. This platform aims to enhance the quality and speed of care delivery […]

Deep Bio is a healthcare AI company that develops deep learning-based cancer diagnostic support software, aiming to advance patient outcomes by empowering clinicians with innovative technology. Their mission is to provide tools that enable medical professionals to make critical decisions, ultimately enhancing healthcare delivery and allowing clinicians to focus more on patient care. The company’s […]

AIRA Matrix is a healthcare AI company that develops cutting-edge artificial intelligence solutions for life sciences applications, with a strong emphasis on deep learning for medical image analysis. Their innovative products and services are designed to enhance diagnostic accuracy, improve workflow efficiency, and reduce turnaround times in pathology laboratories. The company provides diagnostic, prognostic, and […]

AI-LabTest is a secure, AI-powered digital health platform designed to help individuals understand their medical lab reports. The platform analyzes uploaded bloodwork or diagnostic results (in PDF, JPG, or TXT formats) and translates complex medical data into clear, personalized summaries. These summaries highlight key findings, potential implications, and practical next steps in patient-friendly language. The […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.